The Future Prospect of the Neurointervention Industry in the Market

Cerebrovascular disease is a common cause of death in China, with over one million new cases of cerebrovascular disease each year. Acute ischemic stroke (AIS) is caused by thrombotic or embolic occlusion of the cerebral artery, characterized by sudden loss of blood circulation in a certain part of the brain, leading to corresponding neurological dysfunction. AIS has the characteristics of high incidence, high disability rate, high mortality rate, and high recurrence rate.

Neurovascular Intervention Is an Emerging Surgical Approach for the Treatment of Cerebrovascular Diseases and Has Gained Market Recognition

Neurointervention is a technique that uses catheterization technology under the support of digital subtraction angiography (DSA) system to diagnose and treat lesions affecting the human neurovascular system through specific methods such as selective angiography, embolization, dilation, mechanical removal, and drug delivery.

According to different functions and indications, neurovascular intervention devices can be mainly classified into three categories: conduit-type, hemorrhage-type, and ischemic-type.

Conduit-type: mainly used to establish a device delivery pathway from blood vessels to target sites (lesions) for various indications, including sheaths, diagnostic catheters, guiding catheters, intermediate catheters, and occlusion compression systems.

Hemorrhage-type: used for occlusion and embolization of ruptured blood vessels in hemorrhagic cerebrovascular diseases (such as unruptured aneurysms and ruptured aneurysms) and intracranial vascular malformations. Products in this category include microcatheters, microwires, coil springs, balloons, stents, and embolic agents.

Ischemic-type: used for thrombus removal and blood vessel recanalization in ischemic cerebrovascular diseases (such as carotid artery stenosis, unilateral carotid artery stenosis, bilateral carotid artery stenosis). Products in this category include microcatheters, microwires, balloons, stent systems, protection devices, pressure imaging, and suction devices.

The Neurovascular Intervention Industry Is in the Market Introduction Stage and Has Vast Substitution Space in the Future

Neurointerventional treatment in China is still in the market introduction period. Comparing the market development characteristics of interventional treatment fields, it can be seen that the time for neurointerventional treatment to enter China is significantly later than that of coronary intervention treatment, and the market development is obviously lagging behind.

The reasons for this phenomenon are:

On the one hand, the complex structure of the human brain blood vessels and the difficulty of neurointerventional treatment make the requirements for relevant device technology high, resulting in high R&D difficulty for enterprises.

On the other hand, cutting-edge interventional technologies are mastered by foreign medical device giants, making it difficult for Chinese enterprises to compete in the market. In the future, with the maturity of technology, compared with coronary intervention treatment, the neurovascular intervention treatment industry has high substitution space.

Zylox Tonbridge was established in 2012 and its neurovascular product line covers five categories: ischemic, hemorrhagic, cranial artery, stenosis, and vascular access. It is one of the companies in China with the most complete pipeline. Its core products include Dragonfly thrombectomy stent and intracranial aneurysm embolization coil, two of which have obtained CE approval, and multiple products have been granted priority market access through the special approval procedure for innovative medical devices. It is expected that by the end of 2025, 15 neurovascular intervention products will be approved. Its unique "BADDASS" complete clot removal scheme has shown excellent performance in clinical research.